Chapter 6

Additional requirements for premium listing (commercial company)

LR 6 : Additional requirements for premium listing (commercial company)



6.11 **Specialist companies: scientific** research based companies

- 6.11.1 Where a scientific research based company applies for the admission of its equity shares to a premium listing and cannot comply with the minimum three-year period required in ■ LR 6.2.1R(1) because it has been operating for a shorter period:
 - (1) the scientific research based company must have published or filed historical financial information since the inception of its business; and
 - (2) the following apply to the scientific research based company only with regard to the period for which it has published or filed historical financial information under (1):
 - (a) LR 6.2.1R(2), LR 6.2.1R(3) and LR 6.2.1R(4) (content of historical financial information); and
 - (b) LR 6.2.4R and LR 6.2.6R (audit requirements for historical financial information).
- 6.11.2 If the scientific research based company does not comply with either ■ LR 6.2.1R(1) (minimum period for historical financial information) or ■ LR 6.3.1R (revenue earning track record), it must:
 - (1) demonstrate its ability to attract funds from sophisticated investors prior to the marketing at the time of *listing*;
 - (2) intend to raise at least £10 million pursuant to a marketing at the time of *listing*;
 - (3) have a capitalisation, before the marketing at the time of *listing*, of at least £20 million (based on the issue price and excluding the value of any equity shares which have been issued in the six months before listing);
 - (4) have as its primary reason for *listing* the raising of finance to bring identified products to a stage where they can generate significant revenues: and
 - (5) demonstrate that it has a three year record in laboratory research and development including:
 - (a) details of patents granted or details of progress of patent applications; and
 - (b) the successful completion of, or the successful progression of, significant testing of the effectiveness of its products.

LR 6/2